October 27, 2025
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the intersection of law, politics, and commerce.
Massachusetts companies just asked the Supreme Court to overturn federal marijuana prohibition - a move as historic as it is strategically symbolic. State attorneys general are coordinating a national campaign to outlaw intoxicating hemp. Colorado’s testing scandal and Kansas’s crackdown confusion show just how fragmented regulation remains.
Policy, Decoded is powered by THC Group, a boutique consultancy helping clients navigate regulated markets with clarity, strategy, and confidence. If you find this newsletter valuable, imagine what we can do working directly for you.
🎧 And while you’re here - listen to the latest episode of The Hybrid podcast featuring Pam Epstein on hemp’s high-stakes crossroads. A new episode drops this week with Kristin and Eric Rogers of LEVIA, where we talk about how they built, sold, and then reacquired their brand. What does their second act look like?
⚖️ Cannabis heads to SCOTUS
📨 Attorneys general target hemp
🔬 Colorado testing exposes systemic flaws
Start the week sharp.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Massachusetts cannabis companies Canna Provisions, Gyasi Sellers, Wiseacre Farm and Verano Holdings filed a Supreme Court petition Friday asking justices to overturn Gonzales v. Raich, the 2005 decision allowing federal marijuana prohibition under the Commerce Clause. Boies Schiller Flexner argues Raich was "an aberration" in Commerce Clause precedent and that Congress has undermined any link between CSA enforcement and interstate commerce goals by selectively barring enforcement against medical marijuana since 2014 while leaving adult-use programs unprotected. The petition notes 38 states now permit regulated cannabis compared to nine when Raich was decided, and argues DOJ's decade-long non-enforcement policy has "severed any link between controlling state-regulated marijuana and regulating interstate commerce." The First Circuit rejected these arguments in May after district court dismissal, exactly as expected in litigation designed from day one to reach SCOTUS. Justice Clarence Thomas wrote in 2021 that federal policies since Raich have "greatly undermined its reasoning" and called the government's approach "a half-in, half-out regime that simultaneously tolerates and forbids local use of marijuana."
💡 Why It Matters: Four justices must vote to grant cert, and Thomas's 2021 statement is the only concrete signal any justice cares about revisiting Raich. The petition's real audience isn't SCOTUS - it's Trump administration officials deciding whether to finalize Schedule 3 rescheduling, since the constitutional challenge creates political cover to act administratively rather than wait for judicial resolution that might never come. Boies included Verano specifically to make this corporate litigation with institutional investor backing rather than activist cases courts ignore, but that same respectability makes the legal theory less radical than the court typically needs to overturn major precedent. The Commerce Clause argument would eliminate federal enforcement authority over state-legal programs regardless of scheduling, but it requires five conservative justices to decide cannabis federalism matters more than drug prohibition, and nothing in this court's composition suggests that's happening. MSOs privately hope SCOTUS denies cert quickly so they can point to exhausted legal options when lobbying Congress, since the real value of the petition is demonstrating that judicial relief isn't available and legislative action is the only path forward.
🧠 THC Group Take: Thomas's 2021 statement was about federalism principles, not cannabis policy, and the idea that he'll provide a fifth vote to functionally legalize marijuana nationwide is wishful thinking from lawyers who've never watched this court operate. Kavanaugh and Barrett aren't touching this - Kavanaugh's entire judicial philosophy is deference to congressional policy choices, and Barrett has shown zero interest in drug policy cases. Alito and Gorsuch might care about federalism limits on Commerce Clause power, but not enough to hand blue states a win on cannabis when the court just spent three years rolling back state authority on abortion, guns, and environmental regulation. The cert petition's real function is giving Verano and other plaintiffs something to show investors while they wait for Schedule 3 or SAFER Banking, not a serious path to overturning federal prohibition. Boies knows this - you don't spend 20 years in Supreme Court litigation without understanding that cert grants require four votes but winning requires five, and there's no plausible five-vote coalition here. The petition will generate headlines and conference calls with investors, SCOTUS will deny cert without comment sometime in 2026, and the industry will be exactly where it started except with a clearer record that Congress has to act because courts won't.
Fast-moving headlines, flagged for what matters.
Thirty-nine state attorneys general signed a National Association of Attorneys General letter urging appropriations and agriculture committee chairs to ban intoxicating hemp products, calling them synthetic cannabinoids exploiting a perceived Farm Bill loophole. The bipartisan coalition spans adult-use states like California, Colorado, and Illinois alongside prohibition states like Kansas, Indiana, and Alabama, revealing that hemp beverage competition threatens regulated marijuana markets regardless of legalization status. Arkansas AG Tim Griffin, Connecticut AG William Tong, Indiana AG Todd Rokita, and Minnesota AG Keith Ellison co-sponsored the letter citing poison control data showing alarming pediatric exposure increases, framing hemp THC as a child safety crisis rather than adult-use market issue to build bipartisan support. The letter landed during appropriations conference negotiations where Rand Paul already blocked similar ban language once, meaning the coordinated AG pressure is designed to give Republican appropriators political cover to override Paul's objections by framing hemp prohibition as law enforcement consensus rather than marijuana industry protectionism. NAAG's involvement legitimizes the letter as official attorney general coordination rather than individual state complaints, making it harder for hemp industry advocates to dismiss as dispensary lobbying when the national association of state law enforcement chiefs makes the request. (National Association of Attorneys General)
Senator Rand Paul circulated language requiring USDA to study state hemp regulation "best practices" within 18 months, positioning it as an alternative to the consumable hemp ban that nearly made it into Senate agriculture appropriations before Paul threatened to block passage. State attorneys general (read above!) simultaneously drafted a letter urging Republican leaders to ban products with "any quantifiable amount of THC," calling them "Frankenstein THC products" that exploit the Farm Bill, while the House Appropriations Committee approved its own ban version that hasn't reached the floor. Paul's study proposal offers political cover for Republicans wanting to avoid choosing between hemp constituents and law enforcement pressure by kicking the decision past 2026 midterms, but his blocking power only works on bills where he has leverage to hold up passage. The Kentucky split between Paul protecting hemp farmers and McConnell protecting potential marijuana licensees from hemp competition reveals how federal paralysis benefits states that moved quickly to establish regulated markets while punishing states that waited for federal clarity. (Marijuana Moment)
University of Colorado researchers tested 277 products from 52 dispensaries and found 44% of flower products missed Colorado's 15% accuracy threshold, while 96% of concentrates passed. The blind testing study used high-performance liquid chromatography through MedPharm Research, with some flower products testing as much as 8 percentage points below label claims. The gap matters because THC content drives pricing premiums and medical dosing decisions, and Colorado requires testing labs to certify potency despite having no independent verification system until now. The flower accuracy problem appears structural rather than isolated - raw plant material varies by light exposure and curing while concentrates use homogenized oils, but previous California and Washington audits found similar inflation patterns suggesting lab shopping remains profitable. Every mature market faces this dynamic: testing labs compete for cultivation clients who want higher numbers on labels, and regulators lack resources to audit the auditors until academic researchers expose the gap. (University of Colorado Boulder/Scientific Reports)
Kansas legislators learned this week that THC-infused drinks have been selling in liquor stores statewide despite marijuana remaining illegal, with KBI Executive Officer Robert Stuart telling lawmakers the beverages should be outlawed because "if it's intoxicating, it's damaging." Stuart's position conflicts with the 2018 Farm Bill's hemp carveout and puts Kansas in the awkward position of arguing federal law doesn't protect products already flowing through alcohol distribution channels. The KBI began seizing products in October claiming anything over 0.3% THC concentration violates state law, but that threshold applies to plant material by weight - not finished beverages where 5mg or 10mg servings easily clear the percentage calculation. Liquor store owners report sales spiked after the crackdown announcement, and one retailer told reporters products are "flying off the shelves" among Gen X consumers looking for alcohol alternatives. Kansas structured itself into a corner by maintaining strict marijuana prohibition while hemp remained federally legal - now beverages are established in retail channels and the state has no regulatory framework beyond binary prohibition, forcing lawmakers to either accept the category or ban products their constituents are already buying. (Kansas Reflector)
Alabama's ABC Board adopted final rules for HB445 implementation requiring label pre-approval at $50 per SKU, banning packaging with superheroes, cartoon characters, or anything mimicking children's products, and mandating locked storage behind counters invisible from children's sections. The 10mg per serving and 40mg per package caps mirror standard adult-use edible limits, but Alabama's prohibition on online sales and direct delivery creates compliance complications for national brands used to shipping across state lines. Retailers face monthly sales tracking requirements, zero-activity tax filing obligations, and a three-strike penalty structure starting at $1,000, while the ABC Board gained authority to conduct random lab testing of retail inventory without notice. Alabama structured hemp regulation through its alcohol control apparatus rather than creating separate cannabis frameworks, which explains the locked storage and retail channel restrictions that mirror liquor rather than supplement sales. Alabama's commerce clause exposure is significant when hemp remains federally legal and neighboring states allow delivery, creating tension other non-adult-use states will face as they regulate interstate commerce in federally legal products. (AL.com)
Maricopa County Superior Court Judge Randall Warner ruled that Arizona's 2018 Hemp Act legalized the cannabis plant itself but not consumable products derived from it, affirming Attorney General Kris Mayes' position that any THC product sold outside dispensaries violates voter-approved marijuana law. The Hemp Industry Trade Association lost both its preliminary injunction request in June and its full case in August with prejudice, and products disappeared from roughly 850 retail locations while the appeal proceeds through Arizona's Court of Appeals. HITA estimates the crackdown eliminated $699 million in annual business, with retailers reporting complete inventory removal of hemp-derived products rather than risk enforcement despite no fines being issued yet. Warner's statutory interpretation matters because it rejects the argument that federal Farm Bill hemp protections extend to finished consumer products, creating precedent other state courts could follow when dispensary associations pressure attorneys general to protect licensed markets from hemp competition. Arizona's approach differs from Ohio's ban-then-legalize chaos and Texas's executive order middle ground - Mayes used existing voter-approved marijuana law plus judicial interpretation to eliminate hemp products entirely without needing new legislation or regulatory rulemaking. (Phoenix New Times)
Michigan legislators have until December 31 to pass bills transferring hemp oversight from MDARD to USDA's federal program, with House Bill 5094 and Senate Bill 608 both stuck in committee despite farmer complaints that state licensing and testing fees exceed $1,500 annually. MDARD's 2024 report showed only 36 active hemp farmers remain, down from 572 in 2019, as mandatory DEA-registered lab testing 20-30 days before harvest and destruction requirements for any lot testing above 0.3% THC pushed small producers out of the market. The transition delay reflects lawmakers prioritizing intoxicating hemp regulation over industrial hemp reform, as Michigan's Cannabis Regulatory Agency already classifies delta-8 and similar compounds as marijuana requiring dispensary licenses. Michigan's situation mirrors North Dakota, New Mexico, and Maine abandoning state programs due to administrative costs, while larger states like Colorado, Oregon, and Kentucky maintain independent frameworks tied to research institutions and processing infrastructure. The stall matters because farmers make planting decisions for next season now, and continuing under expensive state oversight another year could eliminate what's left of Michigan's industrial hemp cultivation while beverage and extract companies operating under federal rules face no equivalent state compliance burden. (Hemp Today)
Texas DPS adopted final rules implementing the state's medical cannabis expansion, awarding nine licenses December 1 to applicants from a 2023 pool of 139, with three additional licenses going out April 2026. The regulations require satellite locations to maintain enclosed locked storage areas and designate limited personnel with entry authority, while license revocations trigger if operators fail to stock products within 24 months or don't continuously produce at demand levels. Texas structured its expansion to prioritize geographic distribution across public health regions rather than pure market dynamics, meaning license value depends heavily on regional placement and population density in underserved areas. December awards precede most states' 2026 licensing rounds, but the 2023 applicant pool gets first shot at nine of twelve spots before new applicants can compete in April. Texas separated its medical expansion from its hemp crackdown politically, allowing medical program growth while Abbott uses executive orders to restrict hemp THC products that were undercutting the limited medical market.(Marijuana Moment)
Georgia House Speaker Jon Burns' Blue Ribbon Committee concluded four months of hearings Friday after legislative chaos last winter when the Senate blocked medical THC increases while attempting to ban hemp beverages. Medical advocates testified that Georgia's oil-only program with six licensed providers forces patients to buy illegal products, while Georgia Poison Center reported 1,900 pediatric calls since 2022 involving hemp edibles sold at gas stations containing Delta-8, Delta-10, THCP and other variants the state doesn't regulate. Committee Chairman Rep. Mark Newton acknowledged wanting to expand beyond oil-only medical products but noted the difficulty satisfying competing interests, signaling no obvious compromise despite testimony showing seriously ill cancer patients are told they don't qualify as "end stage" enough for the registry. Georgia built the worst regulatory position possible - a medical program so restrictive that physicians won't use it due to federal DEA concerns, while gas stations sell untested products with THC derivatives five times stronger than regulated Delta-9. The testimony record guarantees legislative stalemate because any hemp crackdown gets opposed by medical patients the restricted program excludes, while any medical expansion gets opposed using pediatric poison control data from the unregulated hemp market. (Capitol Beat)
Michigan's Cannabis Regulatory Agency backed legislation allowing immediate license suspension without hearing for egregious violations including untagged product, illicit marijuana in inventory, or refusing to provide records and surveillance footage during investigations. The bills also let CRA continue disciplinary proceedings against operators who close or abandon licenses to evade enforcement, addressing a loophole where bad actors simply walk away from entities facing discipline. County prosecutors testified that current penalties often cap at misdemeanors regardless of scale after court rulings created conflicts between public health code felony provisions and the marijuana regulatory act, making 5,000-plant raids prosecutable only as low-level offenses. Michigan Cannabis Industry Association testified that illicit product entering licensed supply chains compresses prices and undermines compliant operators' investments, requesting reference lab capability to identify synthetic imported product. The transcript shows no committee vote yet, meaning the bills face the usual Michigan dynamic where industry-backed enforcement measures stall because legislators don't want to appear harsh on cannabis while simultaneously raising taxes on legal operators. (Citizen Portal)
South Korea's government designated Yeoncheon County and DMZ border areas as a regulatory sandbox in September, allowing NeoCannBio to cultivate medical cannabis and build GMP facilities for clinical trials and overseas exports after the company extracted high-purity CBD at the Andong Free Regulatory Zone in 2021. The Ministry of Food and Drug Safety must still approve GMP facility construction, but the designation ends restrictions that previously made domestic production impossible despite South Korea legalizing medical cannabis imports in 2018, when only four pharmaceutical products were permitted. Korea currently allows CBD therapeutics but patients face monthly costs exceeding $20,000 because everything is imported, while NeoCannBio claims its extraction technology significantly lowers production costs and the company is pursuing clinical research on CBD combination therapy for lung, liver, colorectal and pancreatic cancers. The regulatory sandbox approach matters because it lets South Korea test domestic cultivation in militarily secure border zones while maintaining strict narcotics controls elsewhere, creating a model other conservative Asian markets could replicate if Korea successfully exports GMP-certified product. Japan fully allowed CBD use last year and France is revising cannabis laws, meaning Korea's domestic production infrastructure positions the country to supply Asian pharmaceutical markets as regional policies liberalize, though the sandbox remains dependent on MFDS approval that could stall if conservative factions push back. (Chosun Biz)
From the hearing room to the comment section — we’re watching it all.
📊 Cannabis-only use hit 10.6% of American adults in 2023 while cigarette-only use dropped to 8.8%, according to NSDUH data analyzed by SUNY and University of Kentucky researchers. The substitution pattern splits by class: cannabis users skew college-educated and higher-income while cigarette smokers remain concentrated among socioeconomically disadvantaged adults. (Addictive Behaviors journal)
📊 The Baltimore Sun analyzed Maryland data showing self-reported cannabis driving doubled from 18% to 39% after 2023 legalization while traffic deaths and DUI arrests stayed flat. Maryland has no legal THC impairment threshold and relies on Drug Recognition Expert evaluations rather than chemical testing standards, meaning the statistics don't distinguish between actual impairment and mere presence of cannabis metabolites in someone's system. (Baltimore Sun)
🌎 Colombian President Gustavo Petro told Trump to legalize marijuana exports and remove agricultural tariffs as an alternative to military strikes on alleged drug trafficking boats, calling U.S. consumption responsible for 300,000 Colombian murders while Treasury sanctioned Petro and his family for alleged cartel involvement. Petro has pushed Colombian legalization since 2022, and a House committee advanced a national legalization bill in August, but Trump calling him an "illegal drug leader" while simultaneously being asked to reschedule marijuana domestically captures the drug war's absurdity perfectly. (Marijuana Moment)